Yun Zhong Recent News
Janney: Nightstar Therapeutics Has 'Significant Upside Potential' With Retinal Disorder Treatments
Janney: 4 Reasons Why Selecta Biosciences Is 'Significantly Undervalued'
Summit Therapeutics' Upcoming Duchenne Muscular Dystrophy Data 'A Strong Catalyst,' Janney Says In Bullish Initiation
Janney: Buy The Dip In Uniqure
Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
SunTrust's 5 Biotech Picks For The Next 6 Months